Hyundai Pharmaceutical Co Ltd - Product Pipeline Review

Global Markets Direct’s, ‘Hyundai Pharmaceutical Co Ltd - Product Pipeline Review - 2016’, provides an overview of the Hyundai Pharmaceutical Co Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Hyundai Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Hyundai Pharmaceutical Co Ltd

The report provides overview of Hyundai Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Hyundai Pharmaceutical Co Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Hyundai Pharmaceutical Co Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Hyundai Pharmaceutical Co Ltd’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hyundai Pharmaceutical Co Ltd

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hyundai Pharmaceutical Co Ltd’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hyundai Pharmaceutical ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hyundai Pharmaceutical Co Ltd Snapshot 7

Hyundai Pharmaceutical Co Ltd Overview 7

Key Facts 7

Hyundai Pharmaceutical Co Ltd - Research and Development Overview 8

Key Therapeutic Areas 8

Hyundai Pharmaceutical Co Ltd - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Hyundai Pharmaceutical Co Ltd - Pipeline Products Glance 14

Hyundai Pharmaceutical Co Ltd - Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

Hyundai Pharmaceutical Co Ltd - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Hyundai Pharmaceutical Co Ltd - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Hyundai Pharmaceutical Co Ltd - Drug Profiles 19

BPS-015 SR - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

choline alfoscerate SR - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

HD-0471042 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

HD-0471953 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

HD-6277 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

HOB-046 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

HOB-047 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

HOB-051 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

HOB-060 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

HOB-071 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

HOB-075 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

HTB-005 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

HTB-006 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

levodropropizine CR - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

tranexamic acid - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

UHC-1 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Hyundai Pharmaceutical Co Ltd - Pipeline Analysis 35

Hyundai Pharmaceutical Co Ltd - Pipeline Products by Target 35

Hyundai Pharmaceutical Co Ltd - Pipeline Products by Route of Administration 36

Hyundai Pharmaceutical Co Ltd - Pipeline Products by Molecule Type 37

Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action 38

Hyundai Pharmaceutical Co Ltd - Dormant Projects 39

Hyundai Pharmaceutical Co Ltd - Locations And Subsidiaries 40

Head Office 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Hyundai Pharmaceutical Co Ltd, Key Facts 7

Hyundai Pharmaceutical Co Ltd - Pipeline by Indication, 2016 9

Hyundai Pharmaceutical Co Ltd - ...

List of Tables

Hyundai Pharmaceutical Co Ltd, Key Facts 7

Hyundai Pharmaceutical Co Ltd - Pipeline by Indication, 2016 9

Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016 10

Hyundai Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016 11

Hyundai Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016 12

Hyundai Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 13

Hyundai Pharmaceutical Co Ltd - Phase III, 2016 14

Hyundai Pharmaceutical Co Ltd - Phase II, 2016 15

Hyundai Pharmaceutical Co Ltd - Phase I, 2016 16

Hyundai Pharmaceutical Co Ltd - Preclinical, 2016 17

Hyundai Pharmaceutical Co Ltd - Discovery, 2016 18

Hyundai Pharmaceutical Co Ltd - Pipeline by Target, 2016 35

Hyundai Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016 36

Hyundai Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016 37

Hyundai Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016 38

Hyundai Pharmaceutical Co Ltd - Dormant Developmental Projects,2016 39

List of Figures

List of Figures

Hyundai Pharmaceutical Co Ltd - Pipeline by Top 10 Indication, 2016 9

Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, ...

List of Figures

Hyundai Pharmaceutical Co Ltd - Pipeline by Top 10 Indication, 2016 9

Hyundai Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016 10

Hyundai Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016 11

Hyundai Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016 12

Hyundai Pharmaceutical Co Ltd - Pipeline by Top 10 Target, 2016 35

Hyundai Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016 36

Hyundai Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016 37

Hyundai Pharmaceutical Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016 38

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports